NeoGenomics, Inc. (NEO)
USD 9.64
(0.78%)
USD 9.64
(0.78%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 591.64 Million USD | 16.07% |
| 2022 | 509.72 Million USD | 5.24% |
| 2021 | 484.32 Million USD | 8.97% |
| 2020 | 444.44 Million USD | 8.71% |
| 2019 | 408.83 Million USD | 47.73% |
| 2018 | 276.74 Million USD | 7.01% |
| 2017 | 258.61 Million USD | 5.95% |
| 2016 | 244.08 Million USD | 144.57% |
| 2015 | 99.8 Million USD | 14.62% |
| 2014 | 87.06 Million USD | 31.0% |
| 2013 | 66.46 Million USD | 11.02% |
| 2012 | 59.86 Million USD | 37.68% |
| 2011 | 43.48 Million USD | 26.51% |
| 2010 | 34.37 Million USD | 16.63% |
| 2009 | 29.46 Million USD | 47.23% |
| 2008 | 20.01 Million USD | 73.97% |
| 2007 | 11.5 Million USD | 77.65% |
| 2006 | 6.47 Million USD | 243.5% |
| 2005 | 1.88 Million USD | 237.83% |
| 2004 | 558.07 Thousand USD | 50.84% |
| 2003 | 369.97 Thousand USD | 295.73% |
| 2002 | 93.49 Thousand USD | 9249.1% |
| 2001 | 1000.00 USD | -99.6% |
| 2000 | 252.4 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 164.5 Million USD | 5.29% |
| 2024 Q3 | 167.82 Million USD | 2.02% |
| 2024 Q1 | 156.24 Million USD | 0.44% |
| 2023 Q3 | 151.95 Million USD | 3.43% |
| 2023 Q4 | 155.55 Million USD | 2.37% |
| 2023 FY | 591.64 Million USD | 16.07% |
| 2023 Q1 | 137.22 Million USD | -1.07% |
| 2023 Q2 | 146.91 Million USD | 7.07% |
| 2022 Q3 | 128.78 Million USD | 2.97% |
| 2022 Q1 | 117.16 Million USD | -6.81% |
| 2022 Q4 | 138.7 Million USD | 7.71% |
| 2022 FY | 509.72 Million USD | 5.24% |
| 2022 Q2 | 125.07 Million USD | 6.74% |
| 2021 Q1 | 115.53 Million USD | -8.3% |
| 2021 Q2 | 121.72 Million USD | 5.36% |
| 2021 Q4 | 125.73 Million USD | 3.62% |
| 2021 FY | 484.32 Million USD | 8.97% |
| 2021 Q3 | 121.34 Million USD | -0.32% |
| 2020 Q4 | 125.99 Million USD | 0.44% |
| 2020 Q2 | 86.97 Million USD | -17.97% |
| 2020 Q1 | 106.03 Million USD | -0.78% |
| 2020 FY | 444.44 Million USD | 8.71% |
| 2020 Q3 | 125.44 Million USD | 44.23% |
| 2019 Q4 | 106.86 Million USD | 2.1% |
| 2019 Q3 | 104.67 Million USD | 2.91% |
| 2019 Q2 | 101.71 Million USD | 6.42% |
| 2019 Q1 | 95.57 Million USD | 24.98% |
| 2019 FY | 408.83 Million USD | 47.73% |
| 2018 Q1 | 63.42 Million USD | -6.44% |
| 2018 Q2 | 67.74 Million USD | 6.82% |
| 2018 Q3 | 69.09 Million USD | 1.99% |
| 2018 Q4 | 76.47 Million USD | 10.68% |
| 2018 FY | 276.74 Million USD | 7.01% |
| 2017 Q3 | 63.05 Million USD | -4.6% |
| 2017 FY | 258.61 Million USD | 5.95% |
| 2017 Q4 | 67.79 Million USD | 7.52% |
| 2017 Q2 | 66.09 Million USD | 7.16% |
| 2017 Q1 | 61.67 Million USD | 1.96% |
| 2016 Q3 | 60.76 Million USD | -3.75% |
| 2016 FY | 244.08 Million USD | 144.57% |
| 2016 Q1 | 59.7 Million USD | 118.86% |
| 2016 Q2 | 63.12 Million USD | 5.74% |
| 2016 Q4 | 60.49 Million USD | -0.45% |
| 2015 Q1 | 23.02 Million USD | -7.9% |
| 2015 Q4 | 27.27 Million USD | 8.57% |
| 2015 Q3 | 25.12 Million USD | 3.1% |
| 2015 FY | 99.8 Million USD | 14.62% |
| 2015 Q2 | 24.37 Million USD | 5.84% |
| 2014 Q4 | 25 Million USD | 7.68% |
| 2014 FY | 87.06 Million USD | 31.0% |
| 2014 Q1 | 18.18 Million USD | -0.77% |
| 2014 Q2 | 20.67 Million USD | 13.68% |
| 2014 Q3 | 23.21 Million USD | 12.32% |
| 2013 Q3 | 16.88 Million USD | 8.21% |
| 2013 Q2 | 15.6 Million USD | -0.34% |
| 2013 Q1 | 15.65 Million USD | 5.12% |
| 2013 FY | 66.46 Million USD | 11.02% |
| 2013 Q4 | 18.32 Million USD | 8.52% |
| 2012 Q1 | 15.16 Million USD | 17.58% |
| 2012 FY | 59.86 Million USD | 37.68% |
| 2012 Q4 | 14.89 Million USD | 4.87% |
| 2012 Q2 | 15.61 Million USD | 2.97% |
| 2012 Q3 | 14.2 Million USD | -9.03% |
| 2011 Q2 | 10.46 Million USD | 18.86% |
| 2011 FY | 43.48 Million USD | 26.51% |
| 2011 Q3 | 11.32 Million USD | 8.16% |
| 2011 Q4 | 12.89 Million USD | 13.9% |
| 2011 Q1 | 8.8 Million USD | 0.57% |
| 2010 Q4 | 8.75 Million USD | 0.54% |
| 2010 FY | 34.37 Million USD | 16.63% |
| 2010 Q3 | 8.7 Million USD | 2.57% |
| 2010 Q1 | 8.41 Million USD | 7.93% |
| 2010 Q2 | 8.49 Million USD | 0.86% |
| 2009 FY | 29.46 Million USD | 47.23% |
| 2009 Q3 | 7.29 Million USD | -2.18% |
| 2009 Q4 | 7.79 Million USD | 6.89% |
| 2009 Q1 | 6.91 Million USD | 16.78% |
| 2009 Q2 | 7.45 Million USD | 7.89% |
| 2008 Q2 | 4.88 Million USD | 17.26% |
| 2008 FY | 20.01 Million USD | 73.97% |
| 2008 Q4 | 5.92 Million USD | 17.22% |
| 2008 Q3 | 5.05 Million USD | 3.47% |
| 2008 Q1 | 4.16 Million USD | 9.68% |
| 2007 Q1 | 2.24 Million USD | 27.22% |
| 2007 Q3 | 3.12 Million USD | 33.22% |
| 2007 Q4 | 3.79 Million USD | 21.54% |
| 2007 FY | 11.5 Million USD | 77.65% |
| 2007 Q2 | 2.34 Million USD | 4.52% |
| 2006 Q4 | 1.76 Million USD | 10.05% |
| 2006 FY | 6.47 Million USD | 243.5% |
| 2006 Q3 | 1.6 Million USD | -9.37% |
| 2006 Q2 | 1.76 Million USD | 31.53% |
| 2006 Q1 | 1.34 Million USD | 78.96% |
| 2005 FY | 1.88 Million USD | 237.83% |
| 2005 Q1 | 230.19 Thousand USD | 69.48% |
| 2005 Q4 | 750.89 Thousand USD | 34.24% |
| 2005 Q3 | 559.34 Thousand USD | 62.18% |
| 2005 Q2 | 344.88 Thousand USD | 49.83% |
| 2004 Q3 | 121.85 Thousand USD | 0.27% |
| 2004 Q2 | 121.53 Thousand USD | -32.05% |
| 2004 FY | 558.07 Thousand USD | 50.84% |
| 2004 Q1 | 178.86 Thousand USD | 30.98% |
| 2004 Q4 | 135.82 Thousand USD | 11.46% |
| 2003 Q1 | 70.16 Thousand USD | 22.81% |
| 2003 Q4 | 136.55 Thousand USD | 51.32% |
| 2003 FY | 369.97 Thousand USD | 295.73% |
| 2003 Q3 | 90.24 Thousand USD | 23.6% |
| 2003 Q2 | 73 Thousand USD | 4.05% |
| 2002 Q4 | 57.13 Thousand USD | 105.02% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | 27.86 Thousand USD | 228.49% |
| 2002 FY | 93.49 Thousand USD | 9249.1% |
| 2002 Q2 | 8484.00 USD | 0.0% |
| 2001 Q2 | 1.00 USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q1 | 1.00 USD | 0.0% |
| 2001 Q3 | - USD | -100.0% |
| 2001 FY | 1000.00 USD | -99.6% |
| 2000 Q2 | 126.23 Thousand USD | 0.06% |
| 2000 Q3 | 1.00 USD | -100.0% |
| 2000 Q4 | - USD | -100.0% |
| 2000 FY | 252.4 Thousand USD | 0.0% |
| 2000 Q1 | 126.16 Thousand USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -1793.318% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -4326.0% |
| Aspira Women's Health Inc. | 9.15 Million USD | -6363.218% |
| Biodesix, Inc. | 49.08 Million USD | -1105.295% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -5955.212% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -23262.023% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -23262.023% |
| Bionano Genomics, Inc. | 36.11 Million USD | -1538.174% |
| CareDx, Inc | 280.32 Million USD | -111.057% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 219.78 Million USD | -169.188% |
| DarioHealth Corp. | 20.35 Million USD | -2807.051% |
| Exact Sciences Corporation | 2.49 Billion USD | 76.332% |
| Fulgent Genetics, Inc. | 289.21 Million USD | -104.57% |
| Guardant Health, Inc. | 563.94 Million USD | -4.911% |
| ICON Public Limited Company | 8.12 Billion USD | 92.714% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 83.839% |
| Illumina, Inc. | 4.5 Billion USD | 86.864% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -18913.003% |
| iSpecimen Inc. | 9.92 Million USD | -5859.227% |
| Standard BioTools Inc. | 106.34 Million USD | -456.369% |
| MDxHealth SA | 70.19 Million USD | -742.88% |
| 23andMe Holding Co. | 219.63 Million USD | -169.372% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 68.627% |
| Myriad Genetics, Inc. | 678.4 Million USD | 12.788% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -65970.003% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| Neogen Corporation | 924.22 Million USD | 35.985% |
| Inotiv, Inc. | 572.42 Million USD | -3.357% |
| Natera, Inc. | 1.08 Billion USD | 45.348% |
| OpGen, Inc. | 3.41 Million USD | -17208.005% |
| OPKO Health, Inc. | 863.49 Million USD | 31.483% |
| Psychemedics Corporation | 22.09 Million USD | -2577.36% |
| Prenetics Global Limited | 21.74 Million USD | -2621.114% |
| Prenetics Global Limited | 21.74 Million USD | -2621.114% |
| Precipio, Inc. | 15.19 Million USD | -3793.157% |
| Personalis, Inc. | 73.48 Million USD | -705.165% |
| RadNet, Inc. | 1.61 Billion USD | 63.403% |
| Sera Prognostics, Inc. | 306 Thousand USD | -193247.386% |
| Sotera Health Company | 1.04 Billion USD | 43.615% |
| Neuronetics, Inc. | 71.34 Million USD | -729.236% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -1192.22% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -1192.22% |
| Trinity Biotech plc | 56.83 Million USD | -941.038% |
| T2 Biosystems, Inc. | 7.19 Million USD | -8125.261% |
| Twist Bioscience Corporation | 312.97 Million USD | -89.039% |
| Exagen Inc. | 52.54 Million USD | -1025.91% |